Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Exercise Therapy for Women With ANOCA (ANOCA Exercise)

24 luglio 2026 aggiornato da: NHS Greater Glasgow and Clyde

Exercise Therapy for Women With ANOCA: a Randomised, Controlled Trial

Angina is a feeling of chest pain or discomfort which can happen if there is reduced blood flow to the heart. Patients can experience angina with no obstructive coronary arteries (ANOCA) which is a difficult condition to treat (ie relieve angina) since few randomised, controlled therapy trials have been undertaken for ANOCA. Until now, angina has been mainly studied in men even though women are at least two-fold more likely than men to experience ANOCA.

In 2023, a Scientific Statement from the American Heart Association affirmed that resistance exercise training can improve or maintain muscle mass and strength and confer favourable physiological and clinical effects on cardiovascular disease and risk factors. Resistance exercise has not been assessed in ANOCA and it offers an important opportunity to study non drug alternatives to treatment for women.

This study will use a resistance based exercise programme to investigate if symptoms of ANOCA can be improved in women. It will recruit at least 76 patients (maximum 152 patients) across 13 hospitals in the UK and the Netherlands.

The study will use a randomised wait list control design. This means all participants will be offered the intervention, but the randomisation will decide when they undergo it.

It is part of a platform of trials for women with ANOCA. We are also setting up a drug study called ANOCA Therapy and a cohort study called ANOCA- Diagnosis.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

There is a gap in knowledge on evidence-based therapy for ANOCA. Stratified medicine is a population-level diagnostic approach for identifying endotypes in a heterogenous population of all-comers. An endotype is defined as a subtype of a condition, which must be characterised by a distinct functional or pathophysiological mechanism.

Use of quantitative noninvasive and invasive diagnostic methods, such as magnetic resonance imaging and coronary function tests involving acetylcholine testing, enables more accurate identification and discrimination of causal endotypes of ANOCA. This is especially relevant for women with ANOCA who have historically been under-recognised.

Quantitative diagnostic methods should bring an end to empirical therapy, therapeutic nihilism and sex disparities in ANOCA.

Precision medicine is different. Precision medicine targets the individual (and their endotype) with a mechanism informed therapy. Accordingly, in this Wellcome Leap Visible project, we will employ a stratified medicine diagnostic approach in women with suspected ANOCA undergoing invasive CFTs in multiple hospitals and then employ a precision medicine strategy by offering each woman an endotype-informed therapy option.

Resistance exercise has not been previously investigated in ANOCA and it therefore represents a novel therapeutic option. This lifestyle intervention will increase the range of trial options, maximize patient choice for participation, and facilitate timely delivery of this project. The beneficial effects of resistance exercise on cardiovascular function have recently been endorsed in a Scientific Statement from the American Heart Association and further supported by a systematic review and favourable experience in our recent randomized trial in Long COVID.

In 2023, a Scientific Statement from the American Heart Association affirmed that resistance exercise training can improve or maintain muscle mass and strength and confer favourable physiological and clinical effects on cardiovascular disease and risk factors. In 19 men with coronary artery disease and endothelial dysfunction, indicated by abnormal acetylcholine-induced coronary vasoconstriction, a randomized controlled trial of aerobic exercise training demonstrated improvements in endothelium-dependent vasodilatation both in epicardial coronary vessels and in resistance vessels. The intervention involved an exercise program six times per day for at least 10 minutes. These results were promising but came with major limitations: no women were included in the study and the exercise program is both burdensome and impractical.

Resistance exercise has not been assessed in ANOCA. Inclusion of a non-CTIMP (lifestyle intervention) brings strategic advantages to our ANOCA platform. A non-medicinal intervention provides an accessible therapy option for women of child-bearing age and for those who may prefer not to participate in an investigational drug trial. This non-CTIMP may also become an option for women who withdraw from a CTIMP, or who complete a CTIMP and are willing to continue into a second trial. The basket trial of resistance exercise may include participants who have completed a precision medicine CTIMP who then wish to participate in the resistance exercise trial or vice versa.

Tipo di studio

Interventistico

Iscrizione (Stimato)

76

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

      • Basildon, Regno Unito
        • Basildon University Hospital
      • Bath, Regno Unito
        • Royal United Hospital Bath
      • Cambridge, Regno Unito
        • Royal Papworth Hospital
      • Glasgow, Regno Unito, G51 4TF
        • Queen Elizabeth University Hospital Clinical Research Facility
        • Contatto:
      • Leeds, Regno Unito
        • Leeds General Infirmary
      • London, Regno Unito
        • Kings College Hospital
      • London, Regno Unito
        • Brompton Hospital
      • London, Regno Unito
        • Guy and St Thomas Hospital
      • Newcastle upon Tyne, Regno Unito
        • Freeman Hospital
        • Contatto:
          • Vijay Kunadian
      • Nottingham, Regno Unito
        • Nottingham City Hospital
      • Sunderland, Regno Unito
        • Sunderland Royal Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  1. Angina with no obstructive coronary arties (ANOCA)
  2. Myocardial perfusion reserve or coronary flow reserve recorded within three years
  3. Seattle Angina Questionnaire frequency score ≤60
  4. Duke Activity Status Index ≤34
  5. Female sex

Exclusion Criteria:

  1. Age <18 years
  2. Unable to provide informed consent
  3. - Unable to comply with the protocol
  4. Pregnancy
  5. Currently undertaking resistance exercise activities

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Intervention
Allocated to exercise intervention first
Participants will undergo daily resistance based exercise for 8 weeks
Comparatore attivo: Control
Allocated to exercise intervention second
Participants will undergo daily resistance based exercise for 8 weeks

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Seattle Angina Questionnaire
Lasso di tempo: Change from Baseline to Week 9
The Seattle Angina Questionnaire a validated 19-item patient-reported survey used to measure coronary artery disease and angina treatment efficacy. Patients will complete on paper or electronically. The scores range from 0 to 100, with higher scores indicating less frequent angina, improved function, and better quality of life.
Change from Baseline to Week 9

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Myocardial perfusion reserve (MPR)
Lasso di tempo: Change from baseline to week 9
The ratio of maximum blood flow in the heart muscle under stress compared to resting flow
Change from baseline to week 9
Handgrip strength using hand dynamometer
Lasso di tempo: Change from baseline to week 9
Measured in Kgs. This is used as a proxy for overall body strength with lower measures indicating less strength.
Change from baseline to week 9
Short Physical Performance Battery (SPPB)
Lasso di tempo: Change from baseline to week 9
Used as a proxy for fitness
Change from baseline to week 9
Brief Illness perception Questionnaire (Brief IPQ)
Lasso di tempo: Change from baseline to week 9
A nine-item scale designed to rapidly assess the cognitive and emotional representations of illness. It consists of 9 items: 8 are scored on a 0-10 scale, and item 9 is an open-ended question assessing perceived causes. The total score (0-80) is calculated by summing the first 8 items, with items 3, 4, and 7 reverse scored. Higher scores generally reflect a more threatening perception of the illness
Change from baseline to week 9
Patient Health Questionnaire-4 of (PHQ4)
Lasso di tempo: Change from Baseline to Week 9
An ultra-brief screening tool used to assess core symptoms of anxiety and depression. Higher scores indicate greater feelings of anxiety and depression.
Change from Baseline to Week 9
Duke Activity Status Index (DASI)
Lasso di tempo: From Baseline to Week 9
A 12-item, self-administered questionnaire used to estimate a patient's functional capacity and peak oxygen uptake. Scores range from 0 to 58.2, with higher scores indicating better physical fitness and lower risk
From Baseline to Week 9
EQ-5D (EQ-5D-5L)
Lasso di tempo: Change from Baseline to Week 9

The EQ-5D evaluates health across 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). It yields three metrics: a 5-digit health profile string, a weighted index value, and a 0-100 self-rated Visual Analogue Scale (VAS) score.

For the 5-digit health profile string higher individual numbers indicate worse health problems.

For the weighted index value a score of 1 indicates perfect health, while 0 represents death.

For the visual analogue score higher numbers here indicate better health

Change from Baseline to Week 9
International Physical Activity Questionnaire (IPAQ)
Lasso di tempo: Change from Baseline to Week 9
Used to obtain comparable estimates of physical activity between populations and countries. Higher scores indicate greater physical activity.
Change from Baseline to Week 9
Fatigue severity scale questionnaire
Lasso di tempo: Change from Baseline to Week 9
Rates level of fatigue. 9 statements assess how fatigue impacts daily life. Each statement is rated on a 7-point Likert scale, ranging from 1 (strongly disagree) to 7 (strongly agree). Higher scores indicate greater fatigue.
Change from Baseline to Week 9
Short Form Post-Exercise Malaise Questionnaire
Lasso di tempo: Change from Baseline to Week 9
measures symptom exacerbation by assessing frequency and severity of symptoms. Higher scores reflect a stronger indication of post exercise malaise.
Change from Baseline to Week 9
Episodes of care (primary, secondary, physiotherapy, rehabilitation)
Lasso di tempo: Week 9
How many times participants engaged with services
Week 9
Hospitalisation for any reason by electronic health record review (where available) up to 4 months (Visit 3)
Lasso di tempo: Week 17
Review of medical notes to see if the patient has been in hospital
Week 17

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Colin Berry, The University of Glasgow

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

14 settembre 2026

Completamento primario (Stimato)

30 giugno 2029

Completamento dello studio (Stimato)

30 giugno 2029

Date di iscrizione allo studio

Primo inviato

20 luglio 2026

Primo inviato che soddisfa i criteri di controllo qualità

24 luglio 2026

Primo Inserito (Effettivo)

29 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

29 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

24 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • GN26CA170

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

A decision will be made by the TSC once the study has ended.

Periodo di condivisione IPD

After the study has completed

Criteri di accesso alla condivisione IPD

Bone fide collaboration request

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .